Vikram Purohit
Stock Analyst at Morgan Stanley
(0.63)
# 3,933
Out of 4,911 analysts
162
Total ratings
23.21%
Success rate
-16.42%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Vikram Purohit
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RXRX Recursion Pharmaceuticals | Assumes: Equal-Weight | $5 | $6.49 | -22.96% | 4 | Jul 3, 2025 | |
| HALO Halozyme Therapeutics | Downgrades: Equal-Weight | $73 → $62 | $58.24 | +6.46% | 7 | May 14, 2025 | |
| ASND Ascendis Pharma | Upgrades: Overweight | $180 → $250 | $167.47 | +49.28% | 19 | May 5, 2025 | |
| INCY Incyte | Maintains: Equal-Weight | $69 → $65 | $70.20 | -7.41% | 24 | Mar 24, 2025 | |
| AXSM Axsome Therapeutics | Maintains: Overweight | $125 → $190 | $100.83 | +88.44% | 19 | Feb 27, 2025 | |
| ZBIO Zenas BioPharma | Maintains: Overweight | $40 → $35 | $15.78 | +121.80% | 2 | Dec 11, 2024 | |
| FHTX Foghorn Therapeutics | Maintains: Equal-Weight | $6 → $9 | $6.19 | +45.40% | 9 | Sep 24, 2024 | |
| GMAB Genmab | Maintains: Equal-Weight | $31 | $23.40 | +32.48% | 2 | Sep 11, 2024 | |
| ABSI Absci | Initiates: Overweight | $7 | $2.89 | +142.21% | 1 | Jul 3, 2024 | |
| ABVX ABIVAX Société Anonyme | Maintains: Equal-Weight | $15 → $16 | $66.49 | -75.94% | 2 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $4.33 | +592.84% | 1 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $20 → $22 | $8.80 | +150.00% | 6 | Feb 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $45 → $10 | $14.86 | -32.71% | 8 | Nov 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $46 → $6 | $3.18 | +88.68% | 1 | Nov 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $43 → $42 | $8.96 | +368.75% | 8 | Aug 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $20 → $23 | $0.92 | +2,345.65% | 4 | Jun 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $38 → $41 | $45.79 | -10.46% | 12 | Dec 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $120 → $40 | $31.69 | +26.22% | 7 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $13 | $3.29 | +295.14% | 1 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $39 → $38 | $22.23 | +70.94% | 6 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $24 → $20 | $11.09 | +80.34% | 5 | Aug 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $11 → $10 | $11.03 | -9.34% | 11 | Jul 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $22 | $1.93 | +1,039.90% | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $40 → $20 | $9.46 | +111.53% | 2 | Aug 5, 2020 |
Recursion Pharmaceuticals
Jul 3, 2025
Assumes: Equal-Weight
Price Target: $5
Current: $6.49
Upside: -22.96%
Halozyme Therapeutics
May 14, 2025
Downgrades: Equal-Weight
Price Target: $73 → $62
Current: $58.24
Upside: +6.46%
Ascendis Pharma
May 5, 2025
Upgrades: Overweight
Price Target: $180 → $250
Current: $167.47
Upside: +49.28%
Incyte
Mar 24, 2025
Maintains: Equal-Weight
Price Target: $69 → $65
Current: $70.20
Upside: -7.41%
Axsome Therapeutics
Feb 27, 2025
Maintains: Overweight
Price Target: $125 → $190
Current: $100.83
Upside: +88.44%
Zenas BioPharma
Dec 11, 2024
Maintains: Overweight
Price Target: $40 → $35
Current: $15.78
Upside: +121.80%
Foghorn Therapeutics
Sep 24, 2024
Maintains: Equal-Weight
Price Target: $6 → $9
Current: $6.19
Upside: +45.40%
Genmab
Sep 11, 2024
Maintains: Equal-Weight
Price Target: $31
Current: $23.40
Upside: +32.48%
Absci
Jul 3, 2024
Initiates: Overweight
Price Target: $7
Current: $2.89
Upside: +142.21%
ABIVAX Société Anonyme
Apr 11, 2024
Maintains: Equal-Weight
Price Target: $15 → $16
Current: $66.49
Upside: -75.94%
Apr 1, 2024
Initiates: Overweight
Price Target: $30
Current: $4.33
Upside: +592.84%
Feb 28, 2024
Maintains: Equal-Weight
Price Target: $20 → $22
Current: $8.80
Upside: +150.00%
Nov 13, 2023
Maintains: Overweight
Price Target: $45 → $10
Current: $14.86
Upside: -32.71%
Nov 7, 2023
Downgrades: Equal-Weight
Price Target: $46 → $6
Current: $3.18
Upside: +88.68%
Aug 29, 2023
Maintains: Overweight
Price Target: $43 → $42
Current: $8.96
Upside: +368.75%
Jun 5, 2023
Maintains: Equal-Weight
Price Target: $20 → $23
Current: $0.92
Upside: +2,345.65%
Dec 19, 2022
Maintains: Equal-Weight
Price Target: $38 → $41
Current: $45.79
Upside: -10.46%
Dec 12, 2022
Maintains: Equal-Weight
Price Target: $120 → $40
Current: $31.69
Upside: +26.22%
Nov 10, 2022
Initiates: Equal-Weight
Price Target: $13
Current: $3.29
Upside: +295.14%
Nov 4, 2022
Maintains: Equal-Weight
Price Target: $39 → $38
Current: $22.23
Upside: +70.94%
Aug 24, 2022
Maintains: Equal-Weight
Price Target: $24 → $20
Current: $11.09
Upside: +80.34%
Jul 25, 2022
Maintains: Underweight
Price Target: $11 → $10
Current: $11.03
Upside: -9.34%
Aug 10, 2021
Initiates: Overweight
Price Target: $22
Current: $1.93
Upside: +1,039.90%
Aug 5, 2020
Maintains: Equal-Weight
Price Target: $40 → $20
Current: $9.46
Upside: +111.53%